Arachidonic Acid News and Research

RSS

Arachidonic acid is an omega-6 fatty acid that is present in the phospholipids (especially phosphatidylethanolamine, phosphatidylcholine and phosphatidylinositides) of membranes of the body's cells, and is abundant in the brain. It is the counterpart to the saturated arachidic acid found in peanut oil.

Orexo fourth quarter net revenues increase to MSEK 109.1

Abstral continues to grow strongly and is now also approved in the USA. OX-MPI has made significant progress towards clinical trials and has received its first milestone payment. The three new programs OX219, OX51 and OX27 announced in August 2010 have now all entered the clinical phase.

16 Feb 2011

Orexo, Invida enter exclusive licensing and distribution agreement for Abstral in Asia Pacific

Orexo AB and Invida Group Private Limited today announced the signing of an exclusive licensing and distribution agreement, covering the Asia Pacific region for Abstral™, Orexo's product for the treatment of breakthrough cancer pain.

14 Jan 2011

12-HETE enzyme inhibition can prevent ischemic retinopathy: Study

The inhibition or removal of an enzyme may prevent or treat ischemic retinopathy by stalling growth of unwanted vessels in the retina, Medical College of Georgia researchers say.

14 Jan 2011

FDA approves Abstral drug for treatment of breakthrough pain in cancer patients

Orexo AB announces today that its partner ProStrakan Group plc has received approval from the US Food and Drug Administration for Abstral. Abstral is licensed for the treatment of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving, and are tolerant to, opioid analgesics for their underlying persistent cancer pain.

10 Jan 2011

Royal DSM to acquire Martek for $1,087 million

Royal DSM N.V., the global Life Sciences and Materials Sciences company, and Martek Biosciences Corporation today announce that they have entered into a definitive agreement under which DSM will acquire all the outstanding shares of common stock of Martek for US$31.50 in cash per share for total consideration of US$1,087 million.

21 Dec 2010

Boehringer Ingelheim's selection of development candidate triggers € 6.5 million milestone payment to Orexo

Orexo AB and Boehringer Ingelheim announced today that Boehringer Ingelheim has selected a development candidate resulting from the worldwide exclusive research, development and commercialisation agreement which Boehringer Ingelheim had signed in November 2005 with Biolipox, a Swedish research-based pharmaceutical company acquired by Orexo in October 2007.

16 Dec 2010

Amira's clinical-stage DP2 receptor antagonist program data to be presented at Pacifichem 2010

Amira Pharmaceuticals, Inc. announced today that it will present preclinical and clinical data from its DP2 receptor antagonist program on December 17, 2010, at Pacifichem 2010 in Honolulu, Hawaii. The data from Amira's clinical-stage DP2 program will be delivered by Brian Stearns, Ph.D., in a presentation titled "Discovery and optimization of a novel series of DP2 antagonists with efficacy in mouse models of COPD and asthma."

15 Dec 2010

Orexo's Abstral sales increases 345% to £14.1m

Orexo AB announces that its sales partner in the EU and USA for Abstral, ProStrakan Group plc yesterday issued its interim report, which gave further information on progress with Abstral, Orexo's leading sublingual fentanyl product for treatment of breakthrough cancer pain.

16 Nov 2010

Study finds canola-type rapeseed oil decreases fibrinogen level

According to research on fatty acids conducted at the universities of Helsinki and Tampere, the consumption of canola-type rapeseed oil decreases the level of fibrinogen detrimental to health in the body. The increased fibrinogen level, caused by an imbalance in essential fats in one's diet, decreases when saturated fatty acids are replaced with rapeseed oil.

9 Nov 2010

Increase in levels of P450 protein creates EET molecules that lower blood pressure

If you are one of the millions of Americans with high blood pressure, more help is on the way. That's because a new research study published in the October 2010 print issue of The FASEB Journal shows that a protein, called P450, metabolizes arachidonic acid in our blood vessel walls to create a tiny molecule with a big name-epoxyeicosatrienoic acid (EET)-which in mice, turns off genes responsible for vascular inflammation and ultimately relaxes blood vessels to lower blood pressure. This protein and genes are also present in humans.

1 Oct 2010

Blood test developed for non-alcoholic fatty liver disease diagnosis

Scientists at the Basque Center for Cooperative Research in Biosciences (CIC bioGUNE) and OWL Genomics Ltd. (Bilbao, Spain), in collaboration with researchers at the INSERM and University Hospitals (APHP Pitié Salpêtrière Hospital, Pierre & Marie Curie University Paris and Centre Hospitalier Universitaire Nice, University of Nice-Sophia-Antipolis, Nice, France), Vanderbilt University (Nashville, US), the University of Southern California (Los Angeles, US), Clinic Hospital and IDIBAPS (Barcelona, Spain) and the Alcalá de Henares University (Alcalá de Henares, Spain) have used metabolomics technology to develop a blood test for non-alcoholic fatty liver disease (NAFLD) diagnosis.

19 Sep 2010

Orexo signs agreement with NewBridge for Abstral drug sale

Orexo AB announces today that an exclusive licensing and distribution agreement has been signed with NewBridge Pharmaceuticals for Abstral, Orexo´s product for the treatment of breakthrough cancer pain.

16 Sep 2010

Martek Biosciences 2010 third quarter revenue increases 51% to $117.2 million

Martek Biosciences Corporation today announced its financial results for the third quarter of fiscal 2010.

2 Sep 2010

Martek extends sole-source supply agreement with Mead Johnson for DHA and ARA for infant formula products

Martek Biosciences Corporation announced today that it has extended its sole-source supply agreement with Mead Johnson & Company, LLC, for DHA (docosahexaenoic acid) and ARA (arachidonic acid) for infant formula products. Under the terms of the amendment, Martek will remain Mead Johnson's global sole-source supplier of DHA and ARA for all of its infant formula products through December 31, 2015, an extension of four years beyond the earliest possible termination date of the current agreement.

21 Jun 2010

Lithium reduces brain inflammation by adjusting metabolism of DHA: Researchers

Though it has been prescribed for over 50 years to treat bipolar disorder, there are still many questions regarding exactly how lithium works. However, in a study appearing in this month's Journal of Lipid Research, researchers have provided solid evidence that lithium reduces brain inflammation by adjusting the metabolism of the health-protective omega-3-fatty acid called DHA.

24 May 2010

Report: 34 C>G of PPAR-γ gene might be a potential therapeutic target for colon cancer

Colorectal cancer is one of the major causes of cancer death in the developed countries. Accumulated evidences indicate that lipid metabolism, especially the one in the arachidonic acid -pathway, appears to play a critical role in the development of CRC.

7 May 2010

Algal DHA improves memory function in healthy aging adults: MIDAS

The Memory Improvement with Docosahexaenoic acid Study published online this week in Alzheimer's & Dementia: The Journal of the Alzheimer's Association showed that algal DHA improved memory function in healthy aging adults, providing a benefit roughly equivalent to having the learning and memory skills of someone three years younger.

4 May 2010

Martek Biosciences completes the acquisition of Amerifit Brands from Charterhouse Group

Martek Biosciences Corporation announced today that it has completed the purchase of Amerifit Brands, Inc. from Charterhouse Group, Inc. in an all-cash transaction valued at approximately $200 million. The acquisition was previously announced January 21, 2010.

15 Feb 2010

New standards proposed to enhance infant formulas and functional foods

New standards to help ensure the quality and enhance the safety of key ingredients widely used in infant formulas and a variety of functional foods are being proposed for inclusion in the Food Chemicals Codex (FCC), an internationally recognized compendium of quality standards for food ingredients.

12 Jan 2010

Tocotrienol form of vitamin E prevents neural cell death and rescues the brain after stroke injury

Blocking the function of an enzyme in the brain with a specific kind of vitamin E can prevent nerve cells from dying after a stroke, new research suggests.